Minerva Neurosciences(US:NERV)2026-03-18 13:32Summary of Minerva Neurosciences Conference Call Company Overview - Company: Minerva Neurosciences (NasdaqCM:NERV) - Focus: Development of roluperidone, a potential treatment for schizophrenia, specifically targeting negative symptoms [1][2] Industry Context - Schizophrenia Symptoms: Schizophrenia is characterized by three types of symptoms: positive, negative, and cognitive deficits. Negative symptoms significantly impair quality of life and are currently not effectively treated by existing antipsychotics [2][3][4] - Negative Symptoms: These include avolition (lack of motivation), which is crucial for patient functioning and quality of life. Current treatments do not address these symptoms adequately, leading to a significant unmet medical need [5][6][7] Core Points and Arguments - Treatment Gap: There is no approved treatment for negative symptoms of schizophrenia in the U.S. as of now, and existing antipsychotics may worsen these symptoms [4][5] - Clinical Trial Design: The company emphasizes the need for innovative trial designs to assess the efficacy of treatments for negative symptoms, suggesting that traditional methods may not be suitable [8][9] - Pharmacology of Roluperidone: Roluperidone works through mechanisms that do not block dopamine, which is believed to help maintain stability in positive symptoms while improving negative symptoms [16][17] - Efficacy Data: In clinical trials, roluperidone showed significant improvements in negative symptoms and functioning, with a low relapse rate when used as monotherapy. The drug was well-tolerated with no significant side effects [22][24][23] Important Data Points - Clinical Trial Results: - The primary endpoint was assessed using the PANSS scale, with significant improvements noted at week 12. The 64 mg dose showed stronger effects compared to the 32 mg dose [19][20] - The first study had a p-value of 0.0001, indicating strong efficacy, while the second study showed a nominal improvement for the 64 mg dose [20][21] - Patient Population: Over 800 patients participated in the trials, with a focus on those with stable positive symptoms and significant negative symptoms [17] Regulatory Considerations - FDA Interactions: The company has engaged in discussions with the FDA regarding trial design and endpoints, aiming to establish a clear path for approval given the lack of existing treatments for negative symptoms [25][26] - Study Design: The upcoming study will compare roluperidone to commonly prescribed antipsychotics, using a double-dummy design to maintain blinding [28] Future Outlook - Timeline for Results: The first patient in the new study is expected to be enrolled in Q2 of the current year, with top-line results anticipated in the second half of next year [41][42] - Regulatory Submission: Following the results, the company plans to re-engage with the FDA regarding NDA submission [42] Additional Considerations - Clinical Meaningfulness: The company is working to establish clinically meaningful effect sizes in collaboration with the FDA, given the absence of approved treatments for negative symptoms [30][31] - Relapse Assessment: The study will include psychometric endpoints and hard clinical endpoints to assess relapse rates and overall patient safety [39][40]